Sanofi US forms digital therapeutics partnership with DarioHealth

By Jenni Spinner contact

- Last updated on GMT

(ArtemisDiana/iStock via Getty Images Plus)
(ArtemisDiana/iStock via Getty Images Plus)

Related tags: Sanofi, Digital therapeutic, Partnership, Research

The pharmaceutical company and the digital therapeutics specialist are joining forces to help accelerate the expansion of various digital health solutions.

DarioHealth, a company focused on digital therapeutics (DTx), has entered into a strategic agreement with Sanofi US, a global healthcare firm. According to Dario, the multi-year, $30m USD agreement is intended to help accelerate the commercial adoption of DarioHealth’s suite of DTx technologies, and to fuel the expansion of digital health solutions on the Dario platform.

The two entities reportedly plan to collaborate on the promotion of Dario’s multi-condition DTx solution, with the intent of increasing Dario's sales reach in the health-plan market, and (to a selective extent) in the employer channel. Further, the agreement calls for Dario and Sanofi to develop new or enhanced solutions leveraging the Dario platform, and for the two companies to work on the generation of robust evidence to support future commercialization in the health plan channel.   

OSP_DarioSanofi_ER
Erez Raphael, CEO, DarioHealth

Dario's single platform is designed to help patients manage diabetes, hypertension, weight management, musculoskeletal and behavioral health. It reportedly will offer Sanofi managed-care clients a scalable digital health solution that creates immediate access across a wide range of needs.

"We are thrilled to be chosen by Sanofi to expand into the digital health market; we believe that this is the first time that a large biopharmaceutical company and a digital health company are collaborating to commercialize digital health solutions in the US market​,” said Erez Raphael, DarioHealth CEO. “Dario's proven digital therapeutic solutions and innovative technologies provide the perfect complement to Sanofi's scientific expertise, market access, and scale, creating a foundation for long-term success in support of Sanofi's goal of expanding into digital health therapies for chronic conditions​.”

OSP_DarioSanofi_GP
Gustavo Pesquin, head of US general medicines, Sanofi

Gustavo Pesquin, head of US general medicines for Sanofi, commented, "Our collaboration with Dario is another step towards accelerating Sanofi's mission of reversing the course of chronic diseases through the integration of healthcare and technology in a way that gives people the tools to improve their health. We are excited to help payers realize the potential digital health can bring to the patient experience, and we look forward to continuing to innovate with Dario on the next generation of chronic condition therapies.​"

Related news

Show more

Related products

show more

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Clear Guidelines for IND/CTA

Clear Guidelines for IND/CTA

Altasciences | 24-Feb-2022 | Technical / White Paper

There are many challenges associated with early drug discovery and development. Advancing your best candidate for regulatory submissions requires a careful...

Follow us

Products

View more

Webinars